# A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

> **NCT03258515** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 45 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** AZD6094 200 mg
- **OTHER:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT03258515
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-06
- **Primary completion:** 2018-03-24
- **Final completion:** 2018-03-24
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2020-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03258515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03258515, "A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03258515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*